# A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care

> **NCT03733444** · PHASE3 · TERMINATED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 781 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** GLPG1690
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03733444
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-05
- **Primary completion:** 2021-03-30
- **Final completion:** 2021-03-30
- **Target enrollment:** 781 (ACTUAL)
- **Why stopped:** The benefit-risk profile no longer supports continuing the study
- **Last updated:** 2022-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03733444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03733444, "A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03733444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*